Cytomorphology of renal angiomyolipoma: performance and accuracy of touch preparation of core needle biopsy

Gelarden, Ian Arthur; Gama, Alcino; Choy, Bonnie

doi:10.1016/j.jasc.2022.12.003

Cited by 1 publication

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cytomorphologic features for other less commonly encountered renal neoplasms have also been described, mostly in case reports and small series. These range from benign neoplasms, such as angiomyolipoma, 83,84 to malignant neoplasms, such as the now molecularly defined TFE3-rearranged RCC. 85,86 The increasing use of RMB will undoubtedly lead to more observations and better recognition of these renal neoplasms on small biopsy specimens.…”

Section: Other Renal Neoplasmsmentioning

confidence: 99%

“…Additional novel therapies, including nonbiologics, small‐molecular drugs, biologics, immunomodulatory therapies, and peptide drugs, are being developed and investigated 96 . Clinical trials using a combination of novel therapies or novel with existing therapies may provide more insight into improving patient outcomes and prolonging patient survival while combatting the challenges of intratumoral heterogeneity in RCC 79–99 …”

Section: Potential Novel Therapies For Rccmentioning

confidence: 99%

See 1 more Smart Citation

Role of renal mass biopsy for diagnosis and management: Review of current trends and future directions

Choy

Nayar

Lin

2023

Cancer Cytopathology

Self Cite

View full text Add to dashboard Cite

The frequency of detection of renal masses has increased over recent decades, causing a concurrent increase in early intervention by surgery. Growing recognition that this approach was contributing to overtreatment led to the broader use of preoperative renal mass biopsy (RMB) by core biopsy and/or fine‐needle aspiration. Because more options for management, such as active surveillance and personalized therapy, are becoming increasingly available, a diagnosis by RMB is becoming a valuable tool for risk stratification and clinical decision making. Guidelines from various professional organizations have outlined situations in which RMB should be used, and it has been shown to be safe and effective. Rapid on‐site evaluation (ROSE) using touch preparations of core biopsy or fine‐needle aspiration smears provides an immediate assessment of adequacy and appropriate triage. ROSE also ensures sufficient material to perform immunohistochemistry and molecular studies for more accurate characterization of renal masses and personalized treatment. The integral role of cytopathology laboratories in precision medicine can also be successfully used in optimizing the workup of RMB from ROSE to final diagnosis, prognostication, and personalized management of kidney tumors. Herein, the authors review their extensive experience working together with interventional radiology and urology colleagues to use core biopsy and ROSE at the time of RMB for diagnosis and management of these lesions.

show abstract